JPMorgan raises target for ORIC Pharmaceuticals stock to USD 26.00

Published on 10/15/2026 at 20:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ORIC posted a USD 0.38 loss per share in the quarter ended August 3, 2026. ORIC stock costs EUR 11.23 on October 15, 2026, up 7.67 percent versus the Tradegate close.

Analyst target and company figures

JPMorgan raised its ORIC target from USD 23.00 to USD 26.00 on October 14, 2026.
ORIC posted a USD 0.38 loss per share for the quarter ended August 3, 2026.
ORIC stock costs EUR 11.23 at Lang & Schwarz on October 15, 2026 at 8:36 p.m. CEST, 7.67 percent above the Tradegate close of October 7, 2026.
ORIC had a USD 1.3 billion market capitalization as of October 15, 2026.

ORIC, US68622P1093, Illustration mit AI erstellt.

JPMorgan raised its price target for ORIC Pharmaceuticals from USD 23.00 to USD 26.00 on October 14, 2026, putting the target 106.84 percent above the USD 12.57 Nasdaq price then available. Markets Insider reported that JPMorgan kept an Overweight rating after meeting with management.

ORIC's latest reported quarter remains an important counterpoint. The company posted a loss of USD 0.38 per share for the quarter ended August 3, 2026, missing the USD 0.36 consensus loss by USD 0.02, according to MarketBeat.

Price position on October 15

ORIC stock had a USD 7.23 to USD 14.68 52-week range on October 14, 2026. The current Nasdaq price of USD 12.57 on October 15, 2026 at 2:39 p.m. ET stood USD 2.11 below the high and USD 5.34 above the low. Trading volume was 668,372 shares at that time, against an average volume of 1,481,779 shares.

The latest euro quotation puts ORIC at EUR 11.23 at Lang & Schwarz on October 15, 2026 at 8:36 p.m. CEST. That is 7.67 percent above the Tradegate close of October 7, 2026 at EUR 10.43. The bid was EUR 11.16 and the ask was EUR 11.29.

Valuation and upcoming dates

ORIC had a USD 1.3 billion market capitalization as of October 15, 2026, while its trailing price-to-earnings ratio was minus 9.32. The company is a clinical-stage biopharmaceutical developer focused on therapies designed to overcome resistance in cancer treatment.

ORIC's investor-relations page listed October 5, 2026 as the date of its agreement with Cancer Research UK to advance a potential CIP2A-targeted therapy into clinical development. The release described the program as a potential first-in-class therapy, while the current analyst target centers attention on the valuation assigned to future clinical progress.

Comparison with peers

ORIC (Nasdaq, USD): plus 7.67 percent, P/E minus 9.32, market capitalization USD 1.3 billion.

Arvinas (Nasdaq, USD): plus 3.74 percent, P/E 44.19, market capitalization USD 456.5 million.

IDEAYA Biosciences (Nasdaq, USD): minus 0.58 percent, P/E minus 17.34, market capitalization USD 3.2 billion.

What the target means for valuation

The JPMorgan target is more than double the latest Nasdaq price, but the comparison rests on a clinical-stage company with negative earnings. For investors, the key tension is the distance between the USD 26.00 target and the current loss-making profile.

Stock stays below its yearly high

ORIC Pharmaceuticals combines a USD 26.00 analyst target with a current Nasdaq price of USD 12.57 and a 52-week high of USD 14.68. The euro quotation was EUR 11.23 at Lang & Schwarz on October 15, 2026 at 8:36 p.m. CEST, 7.67 percent above the Tradegate close of October 7, 2026 at EUR 10.43.

The further course of trading is shown by the continuously updated real-time quote of ORIC Pharmaceuticals stock.